Description
- Degalix injection is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.Â
- The acetate salt of Degarelix injection is a white to off-white amorphous powder.
Degalix is for subcutaneous administration only and is not to be administered intravenously.
Treatment is started with a dose of 240 mg given as two injections of 120 mg each.
The starting dose is followed by maintenance doses of 80 mg administered as a single injection every 28 days.
The common side effects of Degarlix are injection site reactions (e.g., pain, erythema, swelling or induration), hot flashes, increased weight, and increases in serum levels of transaminases and gamma-glutamyltransferase.
Women who are or may become pregnant should not take Degarelix.
Physicians should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmic medications.Â
Therapy with Degarelix results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after Degarelix may be affected. The therapeutic effect of Degarelix should be monitored by measuring serum concentrations of prostatespecific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured.
What is the FDA indication for Degarelix?
The FDA indicated Degarelix for the treatment of prostate cancer.Â
What class of drug is Degarelix?
Degarelix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists.
Is Degarelix a cancer drug?
Degarelix is a hormonal therapy drug used to treat advanced prostate cancer